Xencor (XNCR) Akcija Kursas
Xencor Kursas
Per pastaruosius 14 metus Xencor pajamos augo 23,1 % kasmet ir pasiekė 125,58 mln. USD. Pelnas akcijai augo 19,8 % per metus per pastaruosius 5 metus. Xencor grynoji marža −73,2 % yra sumažėjo palyginti su 30,0 % prieš kelerius metus. Xencor 12 mėn. konsensuso tikslinė kaina yra 27,00 USD, apie žemiau kursą 20,6 %. Iš 20 analitikų 17 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Xencor akcijos kaina
Gaukite šiuos duomenis per Eulerpool API
100 000 užklausų/mėn. nemokamai · be kortelės
Xencor akcija ir akcijų analizė
Dažnai užduodami klausimai apie Xencor akciją
Xencor Inc is a biopharmaceutical company that specializes in the discovery, development, and commercialization of engineered monoclonal antibodies and cytokines for the treatment of severe and life-threatening diseases. Its business model revolves around leveraging its proprietary XmAb® technology platform to engineer superior antibodies with enhanced therapeutic potential. By partnering with pharmaceutical companies, Xencor aims to advance its drug candidates through clinical development and regulatory approval, ultimately aiming to bring innovative and transformative therapies to patients in need. With a focus on innovation, Xencor continues to drive research and development efforts in the field of antibody engineering, positioning itself as a leading player in the biopharmaceutical industry.
Xencor Inc is primarily active in the biotechnology industry.
The main competitors of Xencor Inc in the market include big pharmaceutical companies such as Amgen, Johnson & Johnson, and Roche. These companies are also engaged in the development and commercialization of biopharmaceutical products in various therapeutic areas. Xencor Inc, a leading clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies for treating severe and life-threatening diseases.
Xencor Inc, founded in 1997, is a renowned biopharmaceutical company based in Monrovia, California. With a focus on developing monoclonal antibody therapeutics, Xencor has become a leader in the field of immuno-oncology and autoimmune diseases. The company employs its proprietary XmAb® technology platform, allowing for enhanced antibody engineering and development. Xencor has established numerous strategic partnerships with renowned pharmaceutical companies, leveraging its expertise to create innovative treatments. Recognized for its rigorous scientific approach and commitment to pioneering medicine, Xencor continues to advance its pipeline for potential therapies, aiming to improve patient outcomes in various disease areas.
Xencor Inc, a leading biopharmaceutical company, has achieved several significant milestones since its inception. The company successfully advanced its proprietary XmAb® technology, bringing innovative antibody therapeutics to market. Xencor Inc also forged strategic collaborations with renowned pharmaceutical companies, facilitating the development and commercialization of novel therapies. The company's dedication to research and development resulted in the initiation of multiple clinical trials, highlighting its commitment to addressing unmet medical needs. Xencor Inc's milestones include securing regulatory approvals and advancing therapeutic candidates across a range of diseases, solidifying its position in the biopharmaceutical industry. With its impactful achievements, Xencor Inc continues to drive innovation and improve patient outcomes globally.
Xencor Inc is primarily present in the United States.
Xencor Inc represents values and a corporate philosophy focused on advancing breakthrough medicines for patients. With a commitment to innovation and cutting-edge technology, Xencor is dedicated to transforming the treatment of serious diseases. The company's core values encompass scientific excellence, integrity, collaboration, and resilience. By leveraging its proprietary XmAb® technology, Xencor aims to create next-generation antibody therapeutics that have the potential to deliver improved outcomes for patients. With a robust pipeline and strong research capabilities, Xencor strives to make a meaningful impact in the field of biotechnology, driving advancements in human health.
Analitikai šiuo metu nustato vidutinę Xencor akcijos tikslinę kainą 30,33 USD (mediana: 27,00 USD), t. y. −11,1 % palyginti su paskutine kaina. Konsensusas pagrįstas 20 analitikų reitingais.
20 analitikai šiuo metu vertina Xencor akciją: 17 rekomenduoja pirkti, 3 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Xencor gaus 200,74 mln. USD pajamų ir −2,19 USD pelno akcijai.
Pagal dabartinį kursą Xencor akcija kainuoja 30,97 EUR (34,01 USD).
Xencor akcija (XNCR) kotiruojama 5 biržose, įskaitant: NASDAQ (XNCR), SIX (Zürich) (XE9.SW), Frankfurt (XE9.F), München (XE9.MU), Düsseldorf (XE9.DU).
Xencor Inc is a biopharmaceutical company specializing in the development of protein-based therapeutics and antibodies for the treatment of cancer and autoimmune diseases. The company follows an innovative business model based on proprietary protein engineering technologies. Xencor's product range includes a wide variety of therapeutics and antibodies specifically tailored to the needs of patients with serious diseases. The company's key products include: 1. XmAb Program - A family of antibody platforms based on Xencor's proprietary protein design technology. This platform allows researchers to develop antibodies with improved efficacy and safety. The program has the potential to target a wide range of molecules and therefore serve a broad spectrum of indications. 2. Bispecific Platform - A technology that enables the development of antibodies capable of simultaneously binding to two different target molecules on the surface of cancer cells or immune cells. These bispecifics allow for targeted destruction of cancer cells or activation of immune cells and can therefore offer unique therapeutic possibilities for cancer patients. 3. Xtend-Fc Technology - A platform based on the extension of the half-life of biological drugs. By extending the half-life of therapeutics, they can be administered less frequently, improving patients' quality of life and treatment adherence. The company operates two main business areas: in-house research and partnerships. In the field of in-house research, Xencor focuses on the development of innovative therapeutics that are either marketed on their own or go into product development in partnership with leading pharmaceutical companies. Xencor has an impressive list of collaboration partners where the company provides its technology platforms to jointly develop innovative therapeutics. Key partnerships include Novartis, Merck, Amgen, and Morphosys. Another source of revenue for Xencor is the licensing of its technology platforms and product candidates to other pharmaceutical companies. The company has entered into several licensing agreements with international pharmaceutical and biotech companies, giving it access to new technologies and markets and enabling the global distribution of its products. Xencor Inc has a clear focus on the development of protein-based therapeutics and antibodies. The company pursues a diversified business strategy that focuses on the development of innovative products and platform technologies, as well as collaboration with industry leaders. Through this strategy, Xencor Inc is able to provide patients worldwide with access to a wide range of therapeutics aimed at optimized clinical outcomes and improved safety.
tikėtina pelnas Xencor yra 200,74 mln. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Xencor yra −162,28 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Xencor šiuo metu yra −15,56. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Xencor akcijos vertę.
Kainų ir pardavimų santykis (KUV) Xencor šiuo metu yra 12,58. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Xencor akcijos įvertinimo metrika.
Eulerpool kokybės balas Xencor yra 5/10.
Xencor ISIN yra US98401F1057. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Xencor WKN yra A1W96L. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Xencor prekybos žymė yra XNCR. Ši biržos žymė naudojama Xencor akcijoms prekiauti biržoje.
Xencor akcija
Xencor Pagrindiniai konkurentai
Xencor Biržos simbolis
Xencor FIGI
Visos Xencor pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Xencor akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Xencor. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: